NASDAQ$TOI
Oncology Institute Inc/The · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
The Oncology Institute's Q4 2023 financial performance was presented.
The Oncology Institute is positioned for substantial growth, focusing on its value-based care model within the expanding oncology market. The company's model aims to improve care quality and reduce costs. TOI's revenue growth is demonstrated by its increase in value-based members and expansion into new markets.
- TOI is an early market leader in the oncology market.
- The company operates with a proven and scalable model.
- TOI is well-capitalized, employing a disciplined deployment strategy.
- The company aims to provide high-quality, affordable care to more patients through platform growth.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$85.8M
Revenue by segment
Oncology Institute · $82M total across 3 segments · Q3 2023
- Patient Services$53.6M+20.2%65.4%
- Dispensary$26.8M+42.2%32.7%
- Clinical Trials & Other$1.61M—2.0%
Forward guidance
The Oncology Institute projects revenue between $400 million and $415 million, gross profit between $68 million and $79 million, and adjusted EBITDA between $(8) million and $(18) million for the year 2024.
Tailwinds
- New contracts
- Expand covered lives
- New clinics & providers
- Improve unit economics
- Medicare direct contracting
Headwinds
- Achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.
- The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings.
- TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures are reimplemented.
- Revenue target depends on margin improvement initiatives.
- The forward looking statements should not be relied upon.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro